CCL2 and Hepatic fibrosis: In conclusion, these data indicate differing roles for CCR2-CCL2 and FGF21 pathways in the pathogenesis of liver fibrosis and chronic steatohepatitis in human NAFLD, corroborating the potential distinct benefits of pharmacological targeting each pathway.